Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 7,074.48 | 7,072.97 | 0.02 | 27,547.62 | 25,774.09 | 6.88 |
| Expenses | 6,095.33 | 5,084.05 | 19.89 | 20,419.72 | 19,677.86 | 3.77 |
| Other Income | 206.34 | 221.61 | -6.89 | 861.87 | 746.57 | 15.44 |
| Operating Profit | 979.15 | 1,988.92 | -50.77 | 7,989.77 | 6,842.80 | 16.76 |
| Depreciation | 278.35 | 279.80 | -0.52 | 1,106.95 | 1,051.02 | 5.32 |
| Interest | 14.03 | 14.64 | -4.17 | 62.01 | 89.88 | -31.01 |
| Profit Before Tax | 892.80 | 1,906.96 | -53.18 | 6,820.81 | 5,701.90 | 19.62 |
| Tax | 218.55 | 332.37 | -34.24 | 1,708.35 | 1,696.84 | 0.68 |
| Net Profit | 674.25 | 1,574.59 | -57.18 | 5,291.05 | 4,155.31 | 27.33 |
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,498.08 | 4,970.88 | -9.51 | 19,044.85 | 16,574.34 | 14.91 |
| Expenses | 4,021.25 | 3,309.05 | 21.52 | 13,266.41 | 12,090.19 | 9.73 |
| Other Income | 416.70 | 188.69 | 120.84 | 1,279.38 | 1,433.72 | -10.77 |
| Operating Profit | 3,343.23 | 3,983.78 | -16.08 | 7,057.82 | 5,917.87 | 19.26 |
| Depreciation | 153.33 | 142.62 | 7.51 | 573.89 | 587.59 | -2.33 |
| Interest | 4.03 | 3.55 | 13.52 | 15.11 | 20.25 | -25.38 |
| Profit Before Tax | 736.17 | 1,704.35 | -56.81 | 6,468.82 | 5,310.03 | 21.82 |
| Tax | 119.29 | 266.20 | -55.19 | 1,360.32 | 1,226.69 | 10.89 |
| Net Profit | 616.88 | 1,438.15 | -57.11 | 5,157.65 | 4,077.25 | 26.50 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 7,074.48 | 7,589.44 | -6.79 |
| Expenses | 6,095.33 | 5,694.69 | 7.04 |
| Other Income | 206.34 | 268.95 | -23.28 |
| Operating Profit | 979.15 | 1,894.75 | -48.32 |
| Depreciation | 278.35 | 296.99 | -6.28 |
| Interest | 14.03 | 13.18 | 6.45 |
| Profit Before Tax | 892.80 | 1,853.83 | -51.84 |
| Tax | 218.55 | 500.46 | -56.33 |
| Net Profit | 674.25 | 1,353.37 | -50.18 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,498.08 | 5,225.72 | -13.92 |
| Expenses | 4,021.25 | 3,703.09 | 8.59 |
| Other Income | 416.70 | 254.66 | 63.63 |
| Operating Profit | 3,343.23 | 4,176.76 | -19.96 |
| Depreciation | 153.33 | 141.30 | 8.51 |
| Interest | 4.03 | 2.65 | 52.08 |
| Profit Before Tax | 736.17 | 1,633.34 | -54.93 |
| Tax | 119.29 | 422.81 | -71.79 |
| Net Profit | 616.88 | 1,210.53 | -49.04 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug Administration. As per its latest Enforcement Report, the US-based arm of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication to treat dandruff and skin conditions with inflammation and itching. The Princeton (New Jersey)-based Sun Pharmaceutical Industries Inc is recalling 24,624 bottles of Fluocinolone Acetonide Solution Topical Solution for "Failed Impurities/Degradation Specifications", the US health regulator said. The company initiated the Class III nationwide (US) recall on December 30, 2025. The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris. Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results f
